earKART secures FDA listings across four hearing-aid categories
Key highlights
- earKART completed FDA establishment registration with active listings across four hearing-aid categories.
- Earkart Inc. is a 100%-owned US hearing-care distribution and services subsidiary.
- Earkart Health Limited is a 65%-owned UK distribution and services subsidiary.
- The UK revenue line was Rs 16.25 lakh, or 0.52% of earKART’s Rs 31.07 crore H1 FY27 revenue.
powered by IRIS

earKART completed US Food and Drug Administration (FDA) establishment registration with active medical-device listings in four hearing-aid categories, creating a stated regulatory foundation for exploring US distribution partnerships. The company has also established a 100%-held US distribution subsidiary and holds 65% of a UK distribution and services entity.
Know Earkart inside out
Results, valuation, peers and who's buying, in one view.
What did earKART register with the US FDA?
earKART completed FDA establishment registration with active medical-device listings across four hearing-aid categories: prescription, over-the-counter (OTC), wireless prescription and wireless OTC devices. The presentation calls this a strategic milestone in global expansion and says the registration strengthens the company’s regulatory foundation for international growth opportunities.
The disclosure concerns establishment registration and active device listings, rather than a stated US sales launch, distribution contract or revenue target. The four categories span prescription and OTC products, with wireless variants in both groups, providing listed product categories for the US market identified on page 20 of the presentation.
The distinction is material because earKART says it is exploring US distribution partnerships through retail, online and audiology networks. The presentation does not name a US partner, disclose a commercial agreement, specify a launch date or report US revenue, meaning the registration precedes the partnership and commercialisation steps under consideration.
How are earKART's US and UK operations structured?
earKART operates overseas hearing-care distribution and services through separately incorporated subsidiaries, with a 100% holding in its US entity and a 65% holding in its UK entity. Its disclosed structure also includes a 100%-owned Indian pharmaceutical subsidiary, separating that business from the hearing-care distribution operations.
As at 30 September 2026, the promoter and promoter group held 57.34% of earKART, domestic institutions held 22.20%, and retail investors and others held 20.45%. The group therefore has full ownership of the US distribution vehicle, while retaining a majority rather than complete ownership of the UK operation.
The UK business already appears in earKART’s geographic revenue disclosure for the first half of financial year 2027, or H1 FY27, although the table labels it “Earkart UK.” It recorded Rs 16.25 lakh, equal to 0.52% of total H1 FY27 revenue from operations of Rs 31.07 crore, providing a reported reference point for an existing overseas operation.
What US market opportunity and route to market does earKART identify?
earKART cites a US hearing-aids market projected to rise from US$4.65 billion in 2026 to US$9.57 billion in 2035, representing a compound annual growth rate (CAGR) of 8.4%. Management presents this market projection as context for the FDA registration and the exploration of US distribution routes.
The company identifies three potential channels: retail, online and audiology networks. The four listed categories could serve different channels, as OTC and prescription devices may reach users differently, but earKART has not said which channel it will prioritise or how it will allocate products among them.
Under its “Make in India” approach, earKART says it intends to leverage indigenous product development and manufacturing capabilities to explore international markets. This is a stated strategy rather than an export forecast: the presentation gives no US order book, pricing, shipment schedule, marketing budget or revenue projection for Earkart Inc.
The presentation’s global market forecast offers a comparison with the US outlook. It estimates the worldwide hearing-aid market at US$9.1 billion in 2025 and projects US$17.9 billion by 2035 at a 7.0% CAGR, compared with the 8.4% US CAGR cited for 2026 to 2035; neither forecast is guidance for earKART revenue.
Got a follow-up? Ask IRIS
What operating base can support earKART's international plans?
earKART’s Noida, Uttar Pradesh manufacturing facility covers 13,000 square feet, up from 4,500 square feet at the time of its initial public offering. The site has installed capacity of about 2,00,000 units a year and headroom for a second shift, according to the presentation.
The facility is approved by the Central Drugs Standard Control Organisation and operates to ISO 13485:2016 standards, the company says. Its capabilities include microphone processing, receiver integration, behind-the-ear (BTE) assembly, and in-house printed circuit board assembly integration and testing.
earKART’s product focus includes digitally programmable receiver-in-canal (RIC) and BTE hearing aids under the EQFY, Radius and Fame brands. The company says in-house research and development is driving a shift from analogue products to fully digital, programmable lines, connecting its domestic production base with its international-market exploration.
Revenue and profitability moved in different directions in H1 FY27. Consolidated revenue from operations rose 39.42% year on year to Rs 31.07 crore from Rs 22.29 crore in H1 FY26, while earnings before interest, tax, depreciation and amortisation fell 41.94% to Rs 1.83 crore and the margin declined to 5.90% from 14.00%.
How does earKART's domestic mix compare with its overseas revenue?
earKART remained primarily reliant on domestic government business and Uttar Pradesh in H1 FY27, while the UK contribution was Rs 16.25 lakh. Government revenue was Rs 18.35 crore, or 59.05% of the Rs 31.07 crore total, compared with private revenue of Rs 12.72 crore, or 40.95%.
Uttar Pradesh generated Rs 19.64 crore, or 63.20%, of H1 FY27 revenue, and Gujarat contributed Rs 5.29 crore, or 17.04%. By comparison, the UK revenue line accounted for 0.52%, showing that reported overseas revenue was limited relative to the two largest domestic geographic contributors during the half year.
The company reports presence across 24 states and three Union Territories, alongside the US and UK subsidiaries disclosed in its corporate structure. The 13,000-square-foot Noida facility and its 2,00,000-unit annual installed capacity are the stated manufacturing base as earKART explores international distribution opportunities.
Conclusion
earKART has taken concrete regulatory and corporate-structure steps toward international distribution: FDA establishment registration with active listings across four hearing-aid categories, a 100%-owned US subsidiary and a 65%-owned UK entity. However, its H1 FY27 reported revenue remained centred on domestic government business and Uttar Pradesh, while UK revenue was Rs 16.25 lakh.
The next disclosed development to watch is whether earKART turns its exploration of retail, online or audiology partnerships into named US distribution arrangements. Management has not disclosed a US launch date, partner, order book or sales target, leaving commercial conversion of the four active device-listing categories unresolved.


